BriaCell's Bria-OTS+™ Mechanism of Action Confirmed in Prestigious Peer-Reviewed Cancer Journal

BriaCell's Research Collaboration: BriaCell Therapeutics has published findings on its Bria-OTS+ platform, a personalized immunotherapy developed in collaboration with the US National Cancer Institute (NCI), demonstrating its potential to kill cancer cells.

Mechanism of Action: The study reveals that semi-allogeneic dendritic-cell vaccines can enhance CD4⁺ T-cell help through mismatched MHC class II molecules, which strengthens antigen-specific CD8⁺ T-cell responses against tumors.

Clinical Validation: The publication supports previous encouraging results from BriaCell’s Phase 1/2a study in metastatic breast cancer, providing insights into the mechanism behind their cellular immunotherapy technology.

Company Overview: BriaCell is a clinical-stage biotechnology company focused on developing innovative immunotherapies for cancer treatment, with ongoing trials evaluating their lead candidate, Bria-IMT.